J

Jifeng Feng

Zhejiang Cancer Hospital

ORCID: 0000-0002-7979-2391

Publishes on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers. 498 papers and 34.1k citations.

498Publications

34.1kTotal Citations

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Cancer Immunotherapy and Biomarkers Lung Cancer Diagnosis and Treatment Cancer-related molecular mechanisms research

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Zhendong Chen et al.|The Lancet Oncology|2008

Cited by 5.8k

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al.|The Lancet Oncology|2011

Cited by 4.1k

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al.|The Lancet|2019

Cited by 3.3kOpen Access

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al.|The Lancet|2019

Cited by 2.2k

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al.|The Lancet Oncology|2014

Cited by 2k